{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Benjamin R"],"funding":["NCI NIH HHS"],"pagination":["e833-e843"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11575699"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(11)"],"pubmed_abstract":["<h4>Background</h4>The prognosis for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia remains poor. UCART19, an allogeneic genome-edited anti-CD19 chimeric antigen receptor (CAR) T-cell product derived from healthy donors and available for immediate clinical use, offers a potential therapeutic option for such patients. The CALM trial is a first-in-human study evaluating the safety and antileukaemic activity of UCART19 in adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia.<h4>Methods</h4>This phase 1, open-label study was conducted at eight centres across France, the UK, the USA, and Japan. Adult patients aged 16-70 years with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukaemia who had morphological relapse or a minim"],"journal":["The Lancet. Haematology"],"pubmed_title":["UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial."],"pmcid":["PMC11575699"],"funding_grant_id":["P30 CA016672"],"pubmed_authors":["Mediavilla C","Meunier M","Boucaud F","Pagliuca A","Tremorin MT","Maus M","Madelaine I","Hock H","Metaxa V","Dunlop A","Stewart O","McKeown MA","Yallop D","Gianella-Borradori A","Lewis J","Jain N","Graham C","Bonnin A","Chu V","Devereux S","Sanderson R","Jabbour E","Mason A","Konopleva M","Mathews R","Potter V","Vekhoff A","Bonganay L","Itzykson R","Fouliard S","Clappier E","Dulery R","Marchiq I","Dupouy S","Rice C","Binlich F","Mufti G","Mohty M","Kassam S","Giemza E","Almena-Carrasco M","Caillat-Zucman S","Celli-Lebras K","Frigault MJ","Kebriaei P","Frigault M","Catt L","Jones E","Ellard R","Spitzer T","Farzeneh F","Larghero J","Malard F","Folarin N","Wierda W","Raffoux E","Kato K","Cuthill K","McGee K","Maus MV","Lengline E","Benjamin R","Balandraud S","Casey K","Azoulay E","Teshima T","Chappell J","Cheung G","Munro H","Toncheva V","Rabian F","Pannaux M","Boissel N","CALM Study Group","Kazmi M","Liskova M","Kantarjian H","Daguenel-Nguyen A","Patten P","Brown J","Saleem A","Kuhnl A","Ledraa T","Jozwik A","Brissot E"],"additional_accession":[]},"is_claimable":false,"name":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.","description":"<h4>Background</h4>The prognosis for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia remains poor. UCART19, an allogeneic genome-edited anti-CD19 chimeric antigen receptor (CAR) T-cell product derived from healthy donors and available for immediate clinical use, offers a potential therapeutic option for such patients. The CALM trial is a first-in-human study evaluating the safety and antileukaemic activity of UCART19 in adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia.<h4>Methods</h4>This phase 1, open-label study was conducted at eight centres across France, the UK, the USA, and Japan. Adult patients aged 16-70 years with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukaemia who had morphological relapse or a minim","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2026-06-02T16:11:57.189Z","creation":"2025-04-04T11:42:29.407Z"},"accession":"S-EPMC11575699","cross_references":{"pubmed":["36228643"],"doi":["10.1016/s2352-3026(22)00245-9","10.1016/S2352-3026(22)00245-9"]}}